Lilly Oncology to Highlight Final Results for Phase III Study in Most Common Form of Lung Cancer

PARAMOUNT Study One of More than 25 Lilly Oncology Studies at Key Cancer Meeting

Full press release follows.

SOURCE: Eli Lilly

INDIANAPOLIS, May 14, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will present data from more than 25 studies at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill. from June 1 – 5, 2012, including overall survival results from PARAMOUNT, a Phase III study of an ALIMTA® (pemetrexed for injection)-based continuation maintenance regimen for the treatment of advanced nonsquamous non-small cell lung cancer. Lilly presented progression-free survival data from PARAMOUNT at the 2011 ASCO meeting.

Other Lilly Oncology research being presented at ASCO will include additional clinical data on ALIMTA.

ALIMTA Studies:

Abstract # LBA7507: Oral Abstract Session: Monday, June 4, 2012; 5:15 PM – 5:30 PM
- PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed plus best supportive care versus placebo plus BSC immediately following induction treatment with pem plus cisplatin for advanced nonsquamous non-small cell lung cancer
- Author/Speaker: Luis Paz-Ares
- Location: E Hall D2

Abstract # 7002: Oral Abstract Session: Monday, June 4, 2012; 8:30 AM – 8:45 AM
- Phase II Study of pemetrexed plus carboplatin or cisplatin with concurrent radiation therapy followed by pemetrexed consolidation in patients with favorable-prognosis inoperable stage IIA/B non-small cell lung cancer
- Author/Speaker: Hak Choy
- Location: E Hall D2

P-LLY

This press release contains forward-looking statements about the potential of ALIMTA and reflects Lilly's current beliefs. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. There is no guarantee that the product will continue to be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's filings with the United States Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.

(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO )

SOURCE Eli Lilly and Company

CONTACT: Amy Sousa (Lilly), Office: +1-317-276-8478, Mobile: +1-317-997-1481; Neil Hochman (TogoRun), Office: +1-212-453-2067, Mobile: +1-516-784-9089